Essential Hypertension Treatment in a 52-Year-Old Patient

Initial Treatment Strategy

The American College of Cardiology recommends initiating treatment with an angiotensin-converting enzyme inhibitor (IECA) such as lisinopril 10 mg daily or an angiotensin receptor blocker (ARA-II) such as losartan 50 mg daily as first-line therapy for patients with essential hypertension, including those under 55 years old 1, 2
For patients under 55 years old, IECA or ARA-II is preferred as first-line treatment due to their superior cardiovascular protection in younger patients with higher renin activity 2

Beta-blockers should not be used as first-line treatment for essential hypertension without specific indications, as they have not demonstrated mortality benefits in isolated hypertension 2
Indications for beta-blocker use include previous myocardial infarction, angina pectoris, heart failure (under specialized supervision), and symptomatic tachycardia 1, 3, 4
Contraindications for beta-blocker use include asthma or chronic obstructive pulmonary disease, second- or third-degree heart block, and symptomatic bradycardia 3, 4

The optimal blood pressure target is <130/80 mmHg, with a minimum acceptable target of <140/90 mmHg 1, 2, 4, 5
Blood pressure should be monitored 1-2 weeks after initiating or changing treatment, and every 4-6 months once stable, with evaluation of adherence and adverse effects at each visit 1

Beta-blockers should not be used as first-line treatment for essential hypertension without specific indications, as they have not demonstrated mortality benefits in isolated hypertension 2
The combination of IECA and ARA-II should be avoided due to increased risk of hyperkalemia, syncope, and acute kidney injury without additional cardiovascular benefits 2
The use of hydrochlorothiazide is not recommended when thiazide-like diuretics (chlorthalidone, indapamide) are available, which have better cardiovascular outcomes 2